[go: up one dir, main page]

WO2008023003A8 - Arzneimittelkombinationen zur behandlung von atemwegserkrankungen - Google Patents

Arzneimittelkombinationen zur behandlung von atemwegserkrankungen

Info

Publication number
WO2008023003A8
WO2008023003A8 PCT/EP2007/058653 EP2007058653W WO2008023003A8 WO 2008023003 A8 WO2008023003 A8 WO 2008023003A8 EP 2007058653 W EP2007058653 W EP 2007058653W WO 2008023003 A8 WO2008023003 A8 WO 2008023003A8
Authority
WO
WIPO (PCT)
Prior art keywords
drug combinations
airway diseases
treating airway
drug
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/058653
Other languages
English (en)
French (fr)
Other versions
WO2008023003A1 (de
Inventor
Ingo Konetzki
Thierry Bouyssou
Sabine Pestel
Andreas Schnapp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009525051A priority Critical patent/JP2010501521A/ja
Priority to CA002661496A priority patent/CA2661496A1/en
Priority to AU2007287536A priority patent/AU2007287536A1/en
Priority to EP07802745A priority patent/EP2094271A2/de
Priority to EA200900269A priority patent/EA200900269A1/ru
Priority to MX2009001355A priority patent/MX2009001355A/es
Priority to BRPI0715855-6A priority patent/BRPI0715855A2/pt
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of WO2008023003A1 publication Critical patent/WO2008023003A1/de
Publication of WO2008023003A8 publication Critical patent/WO2008023003A8/de
Priority to NO20090067A priority patent/NO20090067L/no
Priority to IL197125A priority patent/IL197125A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Die vorliegende Erfindung betrifft neue Arzneimittelkombinationen, die neben einer oder mehrerer, bevorzugt einer Verbindung der allgemeinen Formel (1), worin die Reste R1, R2 und R3 die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, wenigstens einen weiteren Wirkstoff 2 enthalten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel.
PCT/EP2007/058653 2006-08-22 2007-08-21 Arzneimittelkombinationen zur behandlung von atemwegserkrankungen Ceased WO2008023003A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002661496A CA2661496A1 (en) 2006-08-22 2007-08-21 Pharmaceutical combinations for the treatment of respiratory diseases
AU2007287536A AU2007287536A1 (en) 2006-08-22 2007-08-21 Drug combinations for treating airway diseases
EP07802745A EP2094271A2 (de) 2006-08-22 2007-08-21 Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
EA200900269A EA200900269A1 (ru) 2006-08-22 2007-08-21 Лекарственные комбинации для лечения заболеваний дыхательных путей
MX2009001355A MX2009001355A (es) 2006-08-22 2007-08-21 Combinaciones farmacologicas para el tratamiento de enfermedades de las vias aereas.
JP2009525051A JP2010501521A (ja) 2006-08-22 2007-08-21 呼吸器疾患治療用医薬組成物
BRPI0715855-6A BRPI0715855A2 (pt) 2006-08-22 2007-08-21 combinaÇÕes farmacÊuticas e o uso das mesmas
NO20090067A NO20090067L (no) 2006-08-22 2009-01-06 Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer
IL197125A IL197125A0 (en) 2006-08-22 2009-02-19 Drug combinations for treating airway diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119272.0 2006-08-22
EP06119272 2006-08-22

Publications (2)

Publication Number Publication Date
WO2008023003A1 WO2008023003A1 (de) 2008-02-28
WO2008023003A8 true WO2008023003A8 (de) 2008-05-22

Family

ID=38535607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/058653 Ceased WO2008023003A1 (de) 2006-08-22 2007-08-21 Arzneimittelkombinationen zur behandlung von atemwegserkrankungen

Country Status (20)

Country Link
US (1) US20080051392A1 (de)
EP (1) EP2094271A2 (de)
JP (1) JP2010501521A (de)
KR (1) KR20090047539A (de)
CN (1) CN101505757A (de)
AR (1) AR062475A1 (de)
AU (1) AU2007287536A1 (de)
BR (1) BRPI0715855A2 (de)
CA (1) CA2661496A1 (de)
CO (1) CO6150168A2 (de)
EA (1) EA200900269A1 (de)
EC (1) ECSP099080A (de)
IL (1) IL197125A0 (de)
MX (1) MX2009001355A (de)
NO (1) NO20090067L (de)
PE (1) PE20081358A1 (de)
TW (1) TW200817009A (de)
UY (1) UY30552A1 (de)
WO (1) WO2008023003A1 (de)
ZA (1) ZA200810828B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones
PE20080610A1 (es) * 2006-08-22 2008-07-15 Boehringer Ingelheim Int Nuevos beta-agonistas enantiomericamente puros, procedimientos para su preparacion y uso como medicamentos
EP2093219A1 (de) 2008-02-22 2009-08-26 Boehringer Ingelheim International Gmbh Kristalline, enantiomerenreine Salzform eines Betamimetikums und dessen Verwendung als Arzneimittel
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026534A1 (de) * 1980-07-12 1982-03-18 C.H. Boehringer Sohn, 6507 Ingelheim 3,1-benzoxazin-2-one, ihre herstellung und verwendung
US4570630A (en) * 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FR2585563B1 (fr) * 1985-07-30 1993-11-12 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
WO2005013993A1 (en) * 2003-07-29 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders
DE102004048390A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pulverinhalativa auf Basis modifizierter Laktosemischungen als Hilfsstoff
DE102005008921A1 (de) * 2005-02-24 2006-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US7423146B2 (en) * 2005-11-09 2008-09-09 Boehringer Ingelheim International Gmbh Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones

Also Published As

Publication number Publication date
PE20081358A1 (es) 2008-10-31
MX2009001355A (es) 2009-02-13
AR062475A1 (es) 2008-11-12
EP2094271A2 (de) 2009-09-02
AU2007287536A1 (en) 2008-02-28
TW200817009A (en) 2008-04-16
CA2661496A1 (en) 2008-02-28
CN101505757A (zh) 2009-08-12
JP2010501521A (ja) 2010-01-21
ECSP099080A (es) 2009-02-27
US20080051392A1 (en) 2008-02-28
UY30552A1 (es) 2008-03-31
ZA200810828B (en) 2009-11-25
EA200900269A1 (ru) 2009-08-28
WO2008023003A1 (de) 2008-02-28
KR20090047539A (ko) 2009-05-12
BRPI0715855A2 (pt) 2013-07-30
IL197125A0 (en) 2009-11-18
CO6150168A2 (es) 2010-04-20
NO20090067L (no) 2009-03-17

Similar Documents

Publication Publication Date Title
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
WO2008003766A3 (en) 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
WO2006032342A3 (de) Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
WO2009007300A3 (en) Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
NO20070089L (no) DPP-IV inhibitorer
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
WO2008009750A3 (en) Macrocyclic compounds useful as bace inhibitors
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
WO2004106307A3 (fr) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
WO2007095021A3 (en) Novel compounds
TW200640911A (en) Novel, long acting betamimetics for the treatment of respiratory diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780031185.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007802745

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009010121

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/001355

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 197125

Country of ref document: IL

Ref document number: 2661496

Country of ref document: CA

Ref document number: 09016427

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12009500344

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2009525051

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200900269

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2007287536

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 575519

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020097005857

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007287536

Country of ref document: AU

Date of ref document: 20070821

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07802745

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0715855

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090220